The correlations of tumor mutational burden among single-region tissue, multi-region tissues and blood in non-small cell lung cancer-Reference-Cited by-全球学者库

登录注册会员服务联系我们

The correlations of tumor mutational burden among single-region tissue, multi-region tissues and blood in non-small cell lung cancer

Published:2019-04-03 Issue:1 Volume:7 Page:
ISSN:2051-1426
Container-title:Journal for ImmunoTherapy of Cancer
language:en
Short-container-title:j. immunotherapy cancer

Author:

Zhang Yaxiong^ORCID,Chang Lianpeng,Yang Yunpeng,Fang Wenfeng,Guan Yanfang,Wu Aiwei,Hong Shaodong,Zhou Huaqiang,Chen Gang,Chen Xi,Zhao Shen,Zheng Qiufan,Pan Hui,Zhang Lanjun,Long Hao,Yang Haoxian,Wang Xin,Wen Zhesheng,Wang Junye,Yang Hong,Xia Xuefeng,Zhao Yuanyuan,Hou Xue,Ma Yuxiang,Zhou Ting,Zhang Zhonghan,Zhan Jianhua,Huang Yan,Zhao Hongyun,Zhou Ningning,Yi Xin,Zhang Li

Funder

National Key R&D Program of China

Science and Technology Program of Guangdong

Science and Technology Program of Guangzhou

Chinese National Natural Science Foundation Project

Pearl River Nova Program of Guangzhou

National Natural Science Funds for Young Scholars of China

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1186/s40425-019-0581-5.pdf

Reference6 articles.

1. Goodman AM, Kato S, Bazhenova L, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017;16:2598–608.

2. Rizvi H, Sanchez-Vega F, La K, et al. Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung Cancer profiled with targeted next-generation sequencing. J Clin Oncol. 2018;36:633–41.

3. Gandara DR, Kowanetz M, Mok TSK, et al. 1295OBlood-based biomarkers for cancer immunotherapy: tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L+ NSCLC (POPLAR and OAK). Ann Oncol. 2017;28.

4. Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545:446–51.

5. Gandara DR, Paul SM, Kowanetz M, et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat Med. 2018;24:1441–8.

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumor mutation burden in the prognosis and response of lung cancer patients to immune-checkpoint inhibition therapies;Translational Oncology;2023-12

2. Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a VEGFR inhibitor anlotinib for pretreated advanced triple negative breast cancer;Signal Transduction and Targeted Therapy;2023-11-17

3. Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB;Journal for ImmunoTherapy of Cancer;2023-11

4. Biomarkers for Immunotherapy in Driver-Gene-Negative Advanced NSCLC;International Journal of Molecular Sciences;2023-09-25

5. Concordance of ctDNA and tissue mutations in NSCLC: A meta-analysis;Cellular and Molecular Biology;2023-08-31

全球学者库

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"全球学者库"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前全球学者库共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2023 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3